510 related articles for article (PubMed ID: 15718321)
1. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.
Ajani JA; Mansfield PF; Crane CH; Wu TT; Lunagomez S; Lynch PM; Janjan N; Feig B; Faust J; Yao JC; Nivers R; Morris J; Pisters PW
J Clin Oncol; 2005 Feb; 23(6):1237-44. PubMed ID: 15718321
[TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
3. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma.
Ajani JA; Mansfield PF; Janjan N; Morris J; Pisters PW; Lynch PM; Feig B; Myerson R; Nivers R; Cohen DS; Gunderson LL
J Clin Oncol; 2004 Jul; 22(14):2774-80. PubMed ID: 15254045
[TBL] [Abstract][Full Text] [Related]
4. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction.
Ajani JA; Correa AM; Walsh GL; Komaki R; Lee JH; Vaporciyan AA; Rice DC; Yao JC; Maru DM; Hofstetter WL; Phan AT; Swisher SG
Cancer; 2010 Apr; 116(7):1656-63. PubMed ID: 20143431
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
Ajani JA; Winter K; Okawara GS; Donohue JH; Pisters PW; Crane CH; Greskovich JF; Anne PR; Bradley JD; Willett C; Rich TA
J Clin Oncol; 2006 Aug; 24(24):3953-8. PubMed ID: 16921048
[TBL] [Abstract][Full Text] [Related]
6. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
7. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma.
Rohatgi PR; Mansfield PF; Crane CH; Wu TT; Sunder PK; Ross WA; Morris JS; Pisters PW; Feig BW; Gunderson LL; Ajani JA
Cancer; 2006 Oct; 107(7):1475-82. PubMed ID: 16944539
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833
[TBL] [Abstract][Full Text] [Related]
9. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report.
Henry LR; Goldberg M; Scott W; Konski A; Meropol NJ; Freedman G; Weiner LM; Watts P; Beard M; McLaughlin S; Cheng JD
Ann Surg Oncol; 2006 Feb; 13(2):214-20. PubMed ID: 16418887
[TBL] [Abstract][Full Text] [Related]
10. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.
Rohatgi P; Swisher SG; Correa AM; Wu TT; Liao Z; Komaki R; Walsh GL; Vaporciyan AA; Rice DC; Roth JA; Ajani JA
Cancer; 2005 Dec; 104(11):2365-72. PubMed ID: 16245310
[TBL] [Abstract][Full Text] [Related]
11. [Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma].
Jiang YY; Wu SX; Zhang P; Xie CY; Wang J; Sun CC
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(31):2171-4. PubMed ID: 19080664
[TBL] [Abstract][Full Text] [Related]
12. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
Javeri H; Arora R; Correa AM; Hofstetter WL; Lee JH; Liao Z; McAleer MF; Maru D; Bhutani MS; Swisher SG; Izzo JG; Ajani JA
Cancer; 2008 Sep; 113(6):1302-8. PubMed ID: 18623381
[TBL] [Abstract][Full Text] [Related]
13. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Hainsworth JD; Gray JR; Thomas M; Whitworth PL; Davis JL; Greco FA
Cancer J Sci Am; 1999; 5(2):84-91. PubMed ID: 10198730
[TBL] [Abstract][Full Text] [Related]
14. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma.
Adelstein DJ; Rice TW; Becker M; Larto MA; Kirby TJ; Koka A; Tefft M; Zuccaro G
Cancer; 1997 Sep; 80(6):1011-20. PubMed ID: 9305700
[TBL] [Abstract][Full Text] [Related]
15. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
16. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB
Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
[TBL] [Abstract][Full Text] [Related]
17. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
18. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG
Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917
[TBL] [Abstract][Full Text] [Related]
19. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
